Skip to content
ModernDoc
Get the app
The research library
COVID-19 / SPECIALTY RESEARCH

PharmacologyIn perspective.

The key COVID-19 findings in pharmacology, distilled into a clear, readable brief. The evidence is here whenever you want to go deeper.

INSIDE THIS MONITOR
48cited sources
18available findings

Study findings updated

AI-assisted evidence summary. For general information. These findings are not individual medical advice or a clinician endorsement.

THE SHORT VERSION

What’s worth knowing.

The key findings, what they mean, and the context that matters.

THE HEADLINE TAKEAWAY-43%

Baricitinib had lower mortality hazard than placebo

In a randomized, double-blind trial of adults hospitalized with COVID-19, baricitinib had a 43% lower relative hazard of mortality than placebo.

The statistic is a relative hazard, not an absolute percentage-point change in mortality.

See the evidence

Baricitinib Mortality

-43%
HR 0.57 (95% CI: 0.41-0.78)

Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9(12):1407-1418.

Citation [9]Original source in a new tab
02

Hospitalization findings differed across higher-risk outpatient studies

Early Paxlovid was linked to fewer hospitalizations or deaths in high-risk nonhospitalized adults. PANORAMIC and CanTreatCOVID found no clear difference for nirmatrelvir/ritonavir in vaccinated higher-risk outpatients.

In the Paxlovid study, treatment started within 5 days of symptoms. These were separate studies, not a head-to-head comparison; reference treatments are not identified, so magnitudes are omitted. The inconclusive results do not prove equal effects.

See the evidence

Reduction in hospitalization/death with Paxlovid in high-risk patients

89%

Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022;386(15):1397-1408.

Citation [3]Original source in a new tab

Hospitalization or death in PANORAMIC trial (vaccinated higher-risk outpatients)

aOR 1.18
95% Bayesian credible interval, 0.55 to 2.62

Butler, Christopher C et al.. Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.. The New England journal of medicine. 2026.

Citation [48]Original source in a new tab

Hospitalization or death in CanTreatCOVID trial (vaccinated higher-risk outpatients)

aOR 0.48
95% Bayesian credible interval, 0.08 to 2.23

Butler, Christopher C et al.. Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.. The New England journal of medicine. 2026.

Citation [48]Original source in a new tab
03

Early remdesivir was associated with lower inpatient mortality

24%lower relative hazard

Compared with no remdesivir, early remdesivir was associated with a 24% lower relative hazard of all-cause inpatient mortality at 14 days and 22% lower at 28 days.

The population was vulnerable patients hospitalized for COVID-19. The study is described as real-world; its design and absolute mortality differences are not otherwise available here.

See the evidence

24% lower relative hazard, calculated from HR 0.76. This is not an absolute percentage-point difference.

14-day all-cause inpatient mortality with early remdesivir vs. no remdesivir

HR 0.76
95% CI: 0.73-0.79

Loubet, Paul et al.. Real-world effectiveness of early remdesivir in reducing mortality among vulnerable patients hospitalized for COVID-19: Evidence for clinical pharmacists and inpatient care providers.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2026.

Citation [46]Original source in a new tab

28-day all-cause inpatient mortality with early remdesivir vs. no remdesivir

HR 0.78
95% CI: 0.75-0.81

Loubet, Paul et al.. Real-world effectiveness of early remdesivir in reducing mortality among vulnerable patients hospitalized for COVID-19: Evidence for clinical pharmacists and inpatient care providers.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2026.

Citation [46]Original source in a new tab
04

Tocilizumab was associated with lower mortality in hospital

A meta-analysis reported lower mortality with tocilizumab among patients hospitalized for COVID-19.

The source addresses IL-6 antagonists broadly, while this result is labeled for tocilizumab. The reference treatment and absolute mortality risks are not identified in this summary.

See the evidence

Tocilizumab Mortality

-14%
OR 0.86 (95% CI: 0.78-0.94)

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA. 2021;326(6):499-518.

Citation [16]Original source in a new tab
05

Acute nirmatrelvir/ritonavir use was linked to lower Long COVID odds

A systematic review and meta-analysis reported lower odds of post-COVID-19 condition after nirmatrelvir/ritonavir use during acute infection in outpatients.

The reference group and absolute risks are not identified in this summary, and the designs of the included studies are not recorded here.

See the evidence

Reduction in post-COVID-19 condition (long COVID) with nirmatrelvir/ritonavir use during acute infection

OR 0.85
95% CI: 0.80-0.91

Cucunawangsih, Cucunawangsih et al.. Impact of nirmatrelvir/ritonavir on the risk of long COVID in outpatients: a systematic review and meta-analysis.. Expert review of anti-infective therapy. 2026.

Citation [47]Original source in a new tab

Study-specific findings. Different populations, treatments and follow-up periods can produce different results.

THE RESEARCH, AS IT ARRIVES

Latest studies.

The newest findings added to this collection.
The learning from each, already distilled.

Study summaries are not available in this collection yet. The original evidence remains accessible in each monitor.

Dates show when findings were added here, not when papers were published. Study populations and comparisons differ.

WHEN YOU WANT TO GO DEEPER
See all 18 findingsOriginal results, comparisons and study details.
7 of 7 source groupsFindings stay together with their study.
SOURCE 031 finding

Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022;386(15):1397-1408.

Read original source in a new tabView citation [3]

Paxlovid Efficacy

89%RRR 89% (95% CI: 60-96%)Source [3]
SOURCE 091 finding

Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9(12):1407-1418.

Read original source in a new tabView citation [9]

Baricitinib Mortality

-43%HR 0.57 (95% CI: 0.41-0.78)Source [9]
SOURCE 161 finding

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA. 2021;326(6):499-518.

Read original source in a new tabView citation [16]

Tocilizumab Mortality

-14%OR 0.86 (95% CI: 0.78-0.94)Source [16]
SOURCE 468 findings

Loubet, Paul et al.. Real-world effectiveness of early remdesivir in reducing mortality among vulnerable patients hospitalized for COVID-19: Evidence for clinical pharmacists and inpatient care providers.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2026.

Read original source in a new tabView citation [46]

14-day all-cause inpatient mortality with early remdesivir treatment

HR 0.7695% CI: 0.73-0.79Source [46]

28-day all-cause inpatient mortality with early remdesivir treatment

HR 0.7895% CI: 0.75-0.81Source [46]
All 8 findings from this source

14-day all-cause inpatient mortality with early remdesivir treatment

HR 0.7695% CI: 0.73-0.79Source [46]

28-day all-cause inpatient mortality with early remdesivir treatment

HR 0.7895% CI: 0.75-0.81Source [46]

14-day all-cause inpatient mortality with early remdesivir vs. no remdesivir

HR 0.7695% CI: 0.73-0.79Source [46]

28-day all-cause inpatient mortality with early remdesivir vs. no remdesivir

HR 0.7895% CI: 0.75-0.81Source [46]

14-day all-cause inpatient mortality with early remdesivir treatment

HR 0.7695% CI: 0.73-0.79Source [46]

28-day all-cause inpatient mortality with early remdesivir treatment

HR 0.7895% CI: 0.75-0.81Source [46]
SOURCE 472 findings

Cucunawangsih, Cucunawangsih et al.. Impact of nirmatrelvir/ritonavir on the risk of long COVID in outpatients: a systematic review and meta-analysis.. Expert review of anti-infective therapy. 2026.

Read original source in a new tabView citation [47]

Reduction in post-COVID-19 condition (long COVID) with nirmatrelvir/ritonavir use during acute infection

OR 0.8595% CI: 0.80-0.91Source [47]

Reduction in post-COVID-19 condition (long COVID) with nirmatrelvir/ritonavir use during acute infection

OR 0.8595% CI: 0.80-0.91Source [47]
SOURCE 484 findings

Butler, Christopher C et al.. Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.. The New England journal of medicine. 2026.

Read original source in a new tabView citation [48]

Hospitalization or death in PANORAMIC trial (vaccinated higher-risk outpatients)

aOR 1.1895% Bayesian credible interval, 0.55 to 2.62Source [48]

Hospitalization or death in CanTreatCOVID trial (vaccinated higher-risk outpatients)

aOR 0.4895% Bayesian credible interval, 0.08 to 2.23Source [48]
All 4 findings from this source

Absolute hospitalization/death rates in PANORAMIC trial

0.8% vs 0.7%Source [48]

Absolute hospitalization/death rates in CanTreatCOVID trial

0.6% vs 1.2%Source [48]
Browse the 48 original sourcesThe complete bibliography behind this monitor.
  1. [1]

    RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693-704.

    Open original source in a new tab
  2. [2]

    RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637-1645.

    Open original source in a new tab
  3. [3]

    Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022;386(15):1397-1408.

    Open original source in a new tab
  4. [4]

    Gottlieb RL, Vaca CE, Paredes R, et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med. 2022;386(4):305-315.

    Open original source in a new tab
  5. [5]

    Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2022;386(6):509-520.

    Open original source in a new tab
  6. [6]

    Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020;383(19):1813-1826.

    Open original source in a new tab
  7. [7]

    ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med. 2021;385(9):790-802.

    Open original source in a new tab
  8. [8]

    REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med. 2021;385(9):777-789.

    Open original source in a new tab
  9. [9]

    Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9(12):1407-1418.

    Open original source in a new tab
  10. [10]

    Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021;384(9):795-807.

    Open original source in a new tab
  11. [11]

    Ramacciotti E, Agati LB, Aguiar VCR, et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet. 2022;399(10319):50-59.

    Open original source in a new tab
  12. [12]

    Reis G, Moreira Silva EAS, Medeiros Silva DC, et al. Early Treatment with Pegylated Interferon Lambda for Covid-19. N Engl J Med. 2023;388(6):518-528.

    Open original source in a new tab
  13. [13]

    Bramante CT, Huling JD, Tignanelli CJ, et al. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. N Engl J Med. 2022;387(7):599-610.

    Open original source in a new tab
  14. [14]

    Bramante CT, Buse JB, Liebovitz DM, et al. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect Dis. 2023;23(10):1119-1129.

    Open original source in a new tab
  15. [15]

    Mukae H, Yotsuyanagi H, Ohmagari N, et al. A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection. Antimicrob Agents Chemother. 2023;67(1):e0124022.

    Open original source in a new tab
  16. [16]

    WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA. 2021;326(6):499-518.

    Open original source in a new tab
  17. [17]

    WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020;324(13):1330-1341.

    Open original source in a new tab
  18. [18]

    WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet. 2022;399(10339):1941-1953.

    Open original source in a new tab
  19. [19]

    Cochrane Collaboration. Antiviral drugs for the treatment of COVID-19. Cochrane Database Syst Rev. 2023.

    Open original source in a new tab
  20. [20]

    Cochrane Collaboration. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev. 2023.

    Open original source in a new tab
  21. [21]

    Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-147.

    Open original source in a new tab
  22. [22]

    Arbel R, Wolff Sagy Y, Hoshen M, et al. Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge. N Engl J Med. 2022;387(9):790-798.

    Open original source in a new tab
  23. [23]

    Shah MM, Joyce B, Plumb ID, et al. Paxlovid Associated with Decreased Hospitalization Rate Among Adults with COVID-19 - United States, April-September 2022. MMWR Morb Mortal Wkly Rep. 2022;71(48):1531-1537.

    Open original source in a new tab
  24. [24]

    Xie Y, Choi T, Al-Aly Z. Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition. JAMA Intern Med. 2023;183(6):554-564.

    Open original source in a new tab
  25. [25]

    Wang L, Berger NA, Davis PB, et al. COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022. Clin Infect Dis. 2023;76(3):e1-e10.

    Open original source in a new tab
  26. [26]

    Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259-264.

    Open original source in a new tab
  27. [27]

    Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med. 2022;28(11):2398-2405.

    Open original source in a new tab
  28. [28]

    National Institutes of Health (NIH). COVID-19 Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/

    Original source link unavailable
  29. [29]

    Infectious Diseases Society of America (IDSA). IDSA Guidelines on the Treatment and Management of Patients with COVID-19.

    Original source link unavailable
  30. [30]

    World Health Organization. Therapeutics and COVID-19: Living Guideline. WHO/2019-nCoV/therapeutics.

    Original source link unavailable
  31. [31]

    CHEST Guidelines and Expert Panel Report. Antithrombotic Therapy in Patients With COVID-19. Chest. 2022;162(1):e64-e68.

    Open original source in a new tab
  32. [32]

    Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374(6575):1586-1593.

    Open original source in a new tab
  33. [33]

    Gupta RK, Nwachuku EL, Wilkinson E, et al. SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms. Cell. 2021;184(26):6291-6303.e10.

    Open original source in a new tab
  34. [34]

    Cele S, Jackson L, Khoury DS, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2022;602(7898):654-656.

    Open original source in a new tab
  35. [35]

    Pretorius E, Vlok M, Venter C, et al. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20(1):172.

    Open original source in a new tab
  36. [36]

    Liverpool COVID-19 Drug Interactions Database. https://www.covid19-druginteractions.org/

    Original source link unavailable
  37. [37]

    FDA. Paxlovid Prescribing Information and Drug Interaction Guidance. 2024.

    Original source link unavailable
  38. [38]

    Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med. 2021;385(21):1941-1950.

    Open original source in a new tab
  39. [39]

    Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 2021;384(3):238-251.

    Open original source in a new tab
  40. [40]

    Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021;384(16):1491-1502.

    Open original source in a new tab
  41. [41]

    INSPIRATION Investigators. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit. JAMA. 2021;325(16):1620-1630.

    Open original source in a new tab
  42. [42]

    Connors JM, Brooks MM, Sciurba FC, et al. Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. JAMA. 2021;326(17):1703-1712.

    Open original source in a new tab
  43. [43]

    Reis G, dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022;10(1):e42-e51.

    Open original source in a new tab
  44. [44]

    Tardif JC, Bouabdallaoui N, L'Allier PL, et al. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respir Med. 2021;9(8):924-932.

    Open original source in a new tab
  45. [45]

    Wong CKH, Au ICH, Lau KTK, et al. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Lancet. 2022;400(10359):1213-1222.

    Open original source in a new tab
  46. [46]

    Loubet, Paul et al.. Real-world effectiveness of early remdesivir in reducing mortality among vulnerable patients hospitalized for COVID-19: Evidence for clinical pharmacists and inpatient care providers.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2026.

    Open original source in a new tab
  47. [47]

    Cucunawangsih, Cucunawangsih et al.. Impact of nirmatrelvir/ritonavir on the risk of long COVID in outpatients: a systematic review and meta-analysis.. Expert review of anti-infective therapy. 2026.

    Open original source in a new tab
  48. [48]

    Butler, Christopher C et al.. Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.. The New England journal of medicine. 2026.

    Open original source in a new tab
ABOUT THIS MONITOR

Understanding includes the limits.

This is an AI-assisted evidence summary, not a clinician endorsement. Read each original paper for its complete methods, population and limitations. Different studies can ask different questions and report different kinds of results.

Dates marked “added” describe when a finding entered this monitor, not when the study was published or clinically reviewed. Personal health and treatment decisions belong in a conversation with a qualified clinician.

How this monitor is made Report a correction
KEEP YOUR QUESTIONS CLOSE

A little more understanding.
Wherever you are.

Explore the ModernDoc app